High specific radioactivity (1R,2S)-4-[18F]fluorometaraminol:: A PET radiotracer for mapping sympathetic nerves of the heart

被引:15
|
作者
Langer, O
Valette, H
Dollé, F
Halldin, C
Loc'h, C
Fuseau, C
Coulon, C
Ottaviani, M
Bottlaender, M
Mazière, B
Crouzel, C
机构
[1] CEA, Serv Hosp Frederic Joliot, Dept Rech Med, F-91401 Orsay, France
[2] Karolinska Inst, Karolinska Hosp, Psychiat Sect, Dept Clin Neurosci, S-10401 Stockholm, Sweden
关键词
(1R; 2S)-4-[F-18]fluorometaraminol; 4-[F-18]FMR; heart; norepinephrine transporter; positron emission tomography;
D O I
10.1016/S0969-8051(00)00082-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The radiolabeled catecholamine analogue (1R,2S)-6-[F-18]fluorometaraminol (6-[F-18]FMR) is a substrate for the neuronal norepinephrine transporter. It has been used as a positron emission tomography (PET) ligand to map sympathetic nerves in dog heart. 6-[F-18]FMR could be only synthesized with low specific radioactivity, which precluded its use in human subjects. We have recently prepared (1R,2S)-4-[F-18]fluorometaraminol (4-[F-18]FMR), a new fluoro-analogue of metaraminol, with high specific radioactivity (56-106 GBq/mu mol). In the present study, we demonstrate in rats that 4-[F-18]FMR possesses similar affinity toward myocardial norepinephrine transport mechanisms as 6-[F-18]FMR. When compared with control animals, an 80% and 76% reduction in myocardial uptake was observed in animals pretreated with desipramine tan inhibitor of the neuronal norepinephrine transporter) and with reserpine (a blocker of the vesicular storage of monoamines), respectively. The entire radioactivity in rat myocardium represented unmetabolized parent tracer as determined by-high performance liquid chromatography analysis of tissue extracts. In dogs, myocardial kinetics of 4-[F-18]FMR were assessed using PET. A rapid and high uptake was observed, followed by prolonged cardiac retention. A heart-to-lung ratio of 15 was reached 10 min after injection of the radiotracer. Pretreatment with desipramine reduced the heart half life of 4-[F-18]FMR by 90% compared with control, Moreover, an infusion of tyramine caused a rapid decline of radioactivity in the heart. This demonstrates that 4-[F-18]FMR specifically visualizes sympathetic neurons in dog heart. High specific radioactivity 4-[F-18]FMR is a promising alternative to 6-[F-18]FMR for myocardial neuronal mapping with PET in humans. NUCL MED BIOL 27;3:233-238, 2000. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:233 / 238
页数:6
相关论文
共 50 条
  • [21] Evaluation of (2S,4S)-4-[18F]FEBGln as a Positron Emission Tomography Tracer for Tumor Imaging
    Huang, Yong
    Liu, Yajing
    Li, Chengze
    Li, Zhongjing
    Chen, Hualong
    Zhang, Lu
    Liang, Ying
    Wu, Zehui
    MOLECULAR PHARMACEUTICS, 2023, 20 (10) : 5195 - 5205
  • [22] [18F]-(2S,4R)4-Fluoroglutamine PET Imaging of Glutamine Metabolism in Murine Models of Hepatocellular Carcinoma (HCC)
    Seo, Youngho
    Craig, Miranda C.
    Murphy, Stephanie T.
    Feng, Jinjin
    Chen, Xin
    Yuneva, Mariia
    MOLECULAR IMAGING, 2022, 2022
  • [23] EXPLOITING GLUTAMINE CONSUMPTION IN INFLAMED ATHEROSCLEROTIC LESIONS BY POSITRON EMISSION TOMOGRAPHY TRACER (2S, 4R)-4-[18F]FLUOROGLUTAMINE
    Palani, S.
    Virta, J.
    Liljenback, H.
    Miner, M. W.
    Li, X. G.
    Knuuti, J.
    Saraste, A.
    Roivainen, A.
    ATHEROSCLEROSIS, 2021, 331 : E31 - E32
  • [24] Evaluation of (2S, 4R)- and (2S, 4S)-4[18F]Fluoro-L-glutamine as tumor metabolic imaging agents
    Ploessl, Karl
    Wang, Limin
    Lieberman, Brian
    Qu, Wenchao
    Kung, Hank
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [25] Comparison of: (2S,4R)-4-[18F]Fluoroglutamine, [11C]Methionine, and 2-Deoxy-2-[18F]Fluoro-D-Glucose and Two Small-Animal PET/CT Systems Imaging Rat Gliomas
    Miner, Maxwell W. G.
    Liljenback, Heidi
    Virta, Jenni
    Helin, Semi
    Eskola, Olli
    Elo, Petri
    Teuho, Jarmo
    Seppala, Kerttu
    Oikonen, Vesa
    Yang, Guangli
    Kindler-Roehrborn, Andrea
    Minn, Heikki
    Li, Xiang-Guo
    Roivainen, Anne
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] Validation of [18F]-(2S,4R)-4-Fluoroglutamine in Multiple Myeloma Mouse Models
    Valtorta, S.
    Chiu, M.
    Toscani, D.
    Sartori, A.
    Coliva, A.
    Brevi, A.
    Taurino, G.
    Grioni, M.
    Ruffini, L.
    Vacondio, F.
    Zanardi, F.
    Bellone, M.
    Moresco, R. M.
    Bussolati, O.
    Giuliani, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S421 - S422
  • [27] Evaluation of (2S,4S)4-(3-[18F]F-propyl)-glutamine as a tumor metabolic imaging agent
    Ploessl, Karl
    Lieberman, Brian
    Zha, Zhihao
    Li, Genxun
    Kung, Hank
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [28] Optimization of Precursor Synthesis Conditions of (2S,4S)4-[18F]FPArg and Its Application in Glioma Imaging
    Huang, Yong
    Zhang, Lu
    Wang, Meng
    Li, Chengze
    Zheng, Wei
    Chen, Hualong
    Liang, Ying
    Wu, Zehui
    PHARMACEUTICALS, 2022, 15 (08)
  • [29] The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), A PET radiotracer designed for the delineation of histone deacetylase expression in cancer
    Zeglis, Brian M.
    Pillarsetty, NagaVaraKishore
    Divilov, Vadim
    Blasberg, Ronald A.
    Lewis, Jason S.
    NUCLEAR MEDICINE AND BIOLOGY, 2011, 38 (05) : 683 - 696
  • [30] Cellular glutamine pool size change in response to glutaminase inhibition detected by [18F](2S, 4R) 4-fluoroglutamine PET
    Pantel, Austin
    Lee, Sharon
    Li, Shihong
    Doot, Robert
    Mach, Robert
    Mankoff, David
    Zhou, Rong
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58